Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: knee

Some Placebos More Effective Than Others in Osteoarthritis

Will Boggs, MD  |  July 28, 2015

NEW YORK (Reuters Health)—Some placebos are more effective than others, and these differences can influence the apparent outcomes of clinical trials, according to a systematic review and meta-analysis of osteoarthritis trials. “More surprising than the fact that all placebos are not equal is the magnitude of that difference,” Dr. Raveendhara R. Bannuru, from Tufts Medical…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:Nonsteroidal anti-inflammatory drugs (NSAIDs)Osteoarthritisplacebo

The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

Thomas R. Collins  |  July 14, 2015

CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…

Filed under:ConditionsDrug UpdatesEducation & TrainingMeeting ReportsProfessional TopicsResearch RheumSystemic Lupus Erythematosus Tagged with:AC&Rclinical symposiumJAK inhibitorLupusOsteoarthritisoutcomepatient careResearchTreatment

How Non-Transferable EHRs Have Affected Physician Practices

Simon M. Helfgott, MD  |  July 13, 2015

Full disclosure: I am not a rabid fan of dogs. None rank among my best friends. Perhaps my antipathy stems from a memorable childhood event, when I was chased down the street where I lived by a neighbor’s large and not-so-friendly hound. He seemed to be twice my size, and this explains why I may…

Filed under:EMRsOpinionPractice SupportRheuminationsSpeak Out RheumTechnology Tagged with:electronic health recordinformation technologypatient carephysician practice

EULAR 2015: The Biology of Fatigue

Thomas R. Collins  |  July 1, 2015

ROME, Italy—Fatigue, a problem experienced frequently by patients with rheumatic diseases, is best thought of as a survival mechanism and as a single phenomenon, not a condition that comes in a variety of forms, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Gene Regulated…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:EULAR

Ethics Forum: Plagiarism in EMRs Saves Time, But Can Raise Risk of Errors

Jane S. Kang, MD, & Robert H. Shmerling, MD  |  June 15, 2015

Case You’ve been asked to see an inpatient for a rheumatologic consultation. After seeing the patient, you enter an initial consult note in the electronic medical record (EMR). The next day, when you write a follow-up note for this patient, you copy part of your assessment and plan from your prior note. Soon after you…

Filed under:EthicsProfessional TopicsTechnology Tagged with:Electronic medical recordsmedical errorsplagiarismTechnology

Medicare Paid Doctors $90 Billion in 2013, up 17%

Reuters Staff  |  June 3, 2015

NEW YORK (Reuters)—Medicare, the government-run health insurance program for elderly and disabled Americans, paid physicians $90 billion in 2013, up 17% from $77 billion in 2012, U.S. healthcare officials reported on Monday. Physician payments accounted for less than one-fifth of Medicare’s 2013 net outlays of $492 billion, which rose from $466 billion in 2012. Payments to…

Filed under:Practice Support Tagged with:MedicarePractice Management

Isometric Exercise May Immediately Reduce Pain of Patellar Tendinopathy

Rob Goodier  |  June 2, 2015

NEW YORK (Reuters Health)—Volleyball players with patellar tendinopathy reported an immediate easing of their pain after isometric exercise, and the effect persisted for 45 minutes after the intervention, a new study has found. In contrast, isotonic exercise appeared to diminish the athletes’ pain to a lesser degree, and the effect did not last at the…

Filed under:ConditionsSoft Tissue Pain Tagged with:isometric exercisekneePainTendinopathy

FDA Issues Safety Alerts for Bisphosphonates & SGLT2 Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  May 20, 2015

Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders

Rheumatologist Recalls Personal Experience with RA

Monica Piecyk, MD  |  May 15, 2015

In late March 2012, I awoke with pain in my left hand. I had difficulty moving my metacarpophalangeal (MCP) joints. They did not move smoothly, but clunked. As I repeatedly attempted to open and close my hand, I realized that I had morning stiffness. As the pain and stiffness gradually improved over the next hour,…

Filed under:ConditionsOpinionPatient PerspectivePractice SupportProfilesRheumatoid ArthritisSpeak Out Rheum Tagged with:DiagnosisManagementPhysician–PatientRheumatoid arthritisrheumatologistSpeak Out Rheumatology

Melioidosis: What Rheumatologists Need to Know

G.C. Yathish, MD, Taral Parikh, MD, Parikshit Sagdeo, MD, Balakrishnan Canchi, MD, and Gurmeet Mangat, MD  |  May 15, 2015

Burkholderia pseudomallei, the causative agent of melioidosis, is endemic in Southeast Asia and northern Australia.1 In recent years, the incidence of melioidosis has increased worldwide. Septic arthritis is a rare, but well-recognized, manifestation of melioidosis. Case Report A 49-year-old woman with known diabetes was admitted elsewhere with uncontrolled diabetes and fever. She was found to…

Filed under:Conditions Tagged with:infectious diseasemelioidosisPainrheumatologistseptic arthritis

  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 78
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences